Greetings and welcome to the Xtant Medical First Quarter 2019 Financial Results Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Carey of Lazar Partners. Thank you. You may begin.

Thank you, operator, and welcome to Xtant Medical’s first quarter 2019 financial results call. Joining me today for the conference call is Greg Jensen, Vice President, Finance and Interim Chief Financial Officer. Today's call is being webcast and will be posted on the company's website for playback. During the course of this call, management may make certain forward-looking statements regarding future events and the company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information, and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intend, and other words with similar meaning. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company’s annual report on Form 10-K filed with the SEC on April 1, 2019. Actual results may differ materially. The company’s financial results, press release, and today’s discussion include certain non-GAAP financial measures. Please refer to the non-GAAP to GAAP reconciliations, which appears in the tables of our press release and are otherwise available on our website. Note that our Form 8-K filed with our financial release press release provides a detailed narrative that describes our use of such measures. For the benefit of those of you who may be listening to the replay, this call was held and recorded on Wednesday, May 15, at approximately 9 AM Eastern Time. The company declines any obligations to update its forward-looking statements except as required by applicable law. Now I'd like to turn the call over to Greg Jensen.

Thank you, David, and good morning to everyone listening. I will begin by providing a general corporate update, followed by a review of our financial results for the first quarter of 2019. As I noted in our last call Xtant’s products meet important needs in spinal fusion procedures and we are committed to realizing both the clinical and commercial value of our product portfolio. We recognize that achieving that objective requires the successful execution of our turnaround strategy, which includes investing in technologies and the personnel needed to provide a strong foundation for future growth. I am pleased to report that we have made important progress. While the impact of this progress is not yet evident in our financial results, we have made progress to expand our sales activities, improve our operational capabilities, and improve our overall financial results. For example, we completed the hiring of our sales team in the first quarter, which is led by Kevin Brandt, Our Chief Commercial Officer. The sales team signed 12 new distributors over the past four months, and we have achieved an improved level of productivity compared to the previous four months. Before providing a detailed overview of our first quarter financial results, I would like to take a moment to put our results in context with respect to our rebuilding strategy. During the first quarter of 2019, we generated a positive EBITDA of $1 million, which demonstrated our continued ability to generate sufficient cash to fund our operations. We know we can achieve long-term profitability simply by cutting costs. Therefore, our growth strategy requires that we make strategic investments in the business, which we want to accomplish from a position of financial strength. We believe we have the necessary working capital resources and support needed to position Xtant for long-term success.…

Thank you, ladies and gentleman. This concludes today’s conference. We thank you for your participation. You may now disconnect your lines and have a wonderful day. End of Q&A: